Cantor Fitzgerald Estimates Cytokinetics FY2025 Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK) – Investment analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for Cytokinetics in a research note issued to investors on Thursday, March 27th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will earn ($4.98) per share for the year, up from their prior estimate of ($5.28). The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share.

Several other research firms also recently commented on CYTK. Royal Bank of Canada increased their price objective on Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Wednesday, December 18th. JMP Securities reaffirmed a “market outperform” rating and set a $78.00 price objective on shares of Cytokinetics in a research note on Friday, February 7th. Stifel Nicolaus started coverage on shares of Cytokinetics in a research note on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 target price on the stock. Citigroup initiated coverage on Cytokinetics in a research report on Friday, February 7th. They issued a “buy” rating and a $86.00 price target for the company. Finally, Evercore ISI upgraded Cytokinetics to a “strong-buy” rating in a research report on Friday, February 7th. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

Cytokinetics Stock Performance

CYTK opened at $43.19 on Monday. Cytokinetics has a 52-week low of $40.53 and a 52-week high of $75.71. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93. The firm’s fifty day simple moving average is $45.75 and its two-hundred day simple moving average is $49.52. The company has a market cap of $5.11 billion, a price-to-earnings ratio of -8.03 and a beta of 0.95.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.03. The business had revenue of $16.93 million for the quarter, compared to analysts’ expectations of $14.26 million.

Insider Buying and Selling at Cytokinetics

In other news, EVP Fady Ibraham Malik sold 2,000 shares of the company’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $49.32, for a total transaction of $98,640.00. Following the completion of the transaction, the executive vice president now directly owns 116,071 shares of the company’s stock, valued at approximately $5,724,621.72. This represents a 1.69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew Callos sold 3,341 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the transaction, the executive vice president now owns 64,434 shares in the company, valued at $2,788,059.18. This represents a 4.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,834 shares of company stock valued at $1,949,275 in the last 90 days. Company insiders own 3.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jones Financial Companies Lllp grew its position in Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 374 shares during the last quarter. Centricity Wealth Management LLC acquired a new position in shares of Cytokinetics during the fourth quarter worth about $29,000. AlphaQuest LLC raised its holdings in Cytokinetics by 113,500.0% during the fourth quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 1,135 shares in the last quarter. J.Safra Asset Management Corp raised its stake in shares of Cytokinetics by 62.1% during the 4th quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock worth $83,000 after buying an additional 671 shares in the last quarter. Finally, Blue Trust Inc. raised its position in Cytokinetics by 85.8% in the fourth quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 842 shares in the last quarter.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.